Drugs / GFH009
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06375733 | Mar 2024 → Dec 2026 expected | large B-cell lymphoma | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05934513 | Sep 2023 → Dec 2025 overdue | peripheral T-cell lymphoma, not otherwise specified | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04588922 | May 2021 → Dec 2026 expected | hematopoietic and lymphoid cell neoplasm | Sellas Life Sciences Group | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05934513 ↗ |
| Known as | SLS009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04588922 ↗ |
| Action | Inhibit | “SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor.” NCT04588922 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05934513 ↗ |
| Target | CDK9 | “SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor.” NCT04588922 ↗ |